Jeffrey Tate, Chief Operating Officer at Cyclo Therapeutics, Inc. (CYTH), bought 2,000 shares at $2.70 ($5K) on 2022-04-29, disclosed to the SEC on 2022-04-29.
Open-market purchase of $5k CYTH by Chief Operating Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.50 | 635 | $2K | 30.0% |
| 2 | $2.70 | 300 | $810 | 15.3% |
| 3 | $2.71 | 1,065 | $3K | 54.6% |
| Total | $2.64 avg | 2,000 | $5K | 100% |
| Filing → |
| CYTH | BUY | 2021-03-30 | $15K | — | Filing → |